Insights Home Insights Featured Content In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process? Article What’s Next for Microsoft and Activision’s Antitrust Battle After EU and UK Decisions The biggest gaming deal in history has hit another regulatory roadblock. As Microsoft continues to seek government approval for their acquisition of Activision, regulators in the UK and EU have announced conflicting opinions on the deal, creating a confusion about what’s to come for the merger. Article Expert Assessment: How the Crypto Crackdown Could Propel Conflict As crypto market players continue looking for concrete guidance regarding industry regulations, how will regulators respond to their requests for action? Read fintech expert Dr. Peter Vinella's insights on what he thinks is next for those in the digital assets space. Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. Other Content White Paper: Theft of Trade Secrets in the Automotive Industry We take a close look at how the EV revolution is igniting an increase in trade secrets disputes and a call for top experts. Insights & News All Practice Areas Pharmaceutical Healthcare Technology Biotechnology Sexual Misconduct & Harassment Wireless Communications Video Gaming Financial Technology Automotive Complex Commercial Life Sciences Intellectual Property Energy & Natural Resources Employment Crisis Management All Trends 2023 Banking Crisis Lab-Grown Foods Wearable Devices Cryptocurrency FDA-Regulated Drugs and Devices Payment Systems Virtual Reality Electric Vehicles Election Law and Voting Rights 5G / 6G Drug and Vaccine Development COVID-19 All Insight Types Archive Article Blog Case Study Event In the News Other Content Press Release Video Search May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. May 1, 2023 — Other Content Juror Attitudes Toward Pharmaceutical Companies A DOAR Research Center report commissioned by WIT reveals important findings from a new survey assessing attitudes toward pharmaceutical companies by potential jurors. April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets. February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP. July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability. June 16, 2021 — Blog Biologics vs. Biosimilars – Driving Innovation, BPCIA Litigation, and a Need for Experts With patents for several existing biological drugs set to expire in the coming decade, biosimilar companies and manufacturers have an opportunity to take advantage. March 10, 2021 — Blog Will COVID-Related Vaccine Development Drive a Globalization of Drug IP Litigation? WIT has been closely watching the impact of recent events, the increasing globalization of patent fights, and how the interplay of these factors will influence domestic drug litigation. December 1, 2020 — Video WIT TV – WIT’s Experience Working on Life Sciences Matters We spoke with Jeremy Scholem, WIT Case Manager, to learn more about his role at WIT and WIT's experience working with attorneys to address their expert witness needs in life sciences matters. October 19, 2020 — Press Release WIT Expert Witness Agency Introduces New Diversity, Equity, and Inclusion Committee to Drive Diversity in the Expert Witness Industry The company commits to providing expert witness opportunities to a more diverse pool of qualified candidates. October 5, 2020 — Video WIT TV – What You Need to Know about WIT Affiliate Experts We sat down with WIT Affiliate Manager, Staci Boyarsky, to learn more about her role and how WIT supports Affiliate Experts. Load More Loading...
In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process?
Article What’s Next for Microsoft and Activision’s Antitrust Battle After EU and UK Decisions The biggest gaming deal in history has hit another regulatory roadblock. As Microsoft continues to seek government approval for their acquisition of Activision, regulators in the UK and EU have announced conflicting opinions on the deal, creating a confusion about what’s to come for the merger.
Article Expert Assessment: How the Crypto Crackdown Could Propel Conflict As crypto market players continue looking for concrete guidance regarding industry regulations, how will regulators respond to their requests for action? Read fintech expert Dr. Peter Vinella's insights on what he thinks is next for those in the digital assets space.
Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
Other Content White Paper: Theft of Trade Secrets in the Automotive Industry We take a close look at how the EV revolution is igniting an increase in trade secrets disputes and a call for top experts.
May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
May 1, 2023 — Other Content Juror Attitudes Toward Pharmaceutical Companies A DOAR Research Center report commissioned by WIT reveals important findings from a new survey assessing attitudes toward pharmaceutical companies by potential jurors.
April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets.
February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP.
July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability.
June 16, 2021 — Blog Biologics vs. Biosimilars – Driving Innovation, BPCIA Litigation, and a Need for Experts With patents for several existing biological drugs set to expire in the coming decade, biosimilar companies and manufacturers have an opportunity to take advantage.
March 10, 2021 — Blog Will COVID-Related Vaccine Development Drive a Globalization of Drug IP Litigation? WIT has been closely watching the impact of recent events, the increasing globalization of patent fights, and how the interplay of these factors will influence domestic drug litigation.
December 1, 2020 — Video WIT TV – WIT’s Experience Working on Life Sciences Matters We spoke with Jeremy Scholem, WIT Case Manager, to learn more about his role at WIT and WIT's experience working with attorneys to address their expert witness needs in life sciences matters.
October 19, 2020 — Press Release WIT Expert Witness Agency Introduces New Diversity, Equity, and Inclusion Committee to Drive Diversity in the Expert Witness Industry The company commits to providing expert witness opportunities to a more diverse pool of qualified candidates.
October 5, 2020 — Video WIT TV – What You Need to Know about WIT Affiliate Experts We sat down with WIT Affiliate Manager, Staci Boyarsky, to learn more about her role and how WIT supports Affiliate Experts.
